You are here
Rep. Dan Maffei, Bio/Med Leaders Discuss Ways to Address Job Creation, Manufacturing/R&D Leadership
Auburn, NY (August 21, 2014) – Leaders of New York’s bioscience and medical technology (Bio/Med) industry joined U.S. Rep. Dan Maffei (D-NY) today to address how companies within the sector can drive the state’s economic competitiveness and future growth. The roundtable took place at the Auburn manufacturing facility of New York-based Volpi.
Nearly 20,000 employees work for medical technology companies in New York, and overall the industry supports a total of 47,000 jobs, contributing $7.4 billion to the state’s economy. The Bio/Med industry as a whole directly employs nearly 75,000 New York State residents, including pharma, biotech and medical device sectors.
Still, as participants in the roundtable noted today, this positive impact must be sustained by policies that support continued investment in the development of new technologies and the creation of new jobs.
“As Congressman Maffei has demonstrated today, it’s important for everyone to recognize the economic contributions made by the Bio/Med industry in New York State,” said Jessica Crawford, president of MedTech, which represents the state’s pharmaceutical, bioscience and medical technology industry. “New York has a lot of room for advancement and MedTech looks forward to working with our members and legislators to improve upon the business environment that will support and grow our Bio/Med ecosystem.”
Medical technology also is a major contributor to medical progress, improving health, lowering long-term health care costs, reducing recovery times, and improving productivity. Between 1980 and 2000, medical progress added more than three years to life expectancy. The death rate from heart disease was cut in half, the death rate from stroke was cut by one-third, and the death rate from breast cancer was reduced by 20 percent.
“We are pleased Rep. Maffei helped lead our discussion on the importance of supporting medical technology companies at the federal level,” said JC Scott, senior executive vice president of the Advanced Medical Technology Association (AdvaMed). “We appreciated the opportunity to highlight for Rep. Maffei the importance of advancing public policies that support innovation, including repeal of the device tax, an efficient FDA regulatory process and a more predictable and transparent reimbursement process.”
“From economic impact to improvements in quality of care, medical technology is a driver of a stronger America. New York is an example of how states can also benefit from a vibrant medical technology sector,” said Crawford. “We believe by embracing a policy agenda that advances economic growth, the United States can chart a path for a dynamic medical technology sector that improves lives around the world.”
Other participants in the panel included MedTech members from Volpi, Welch Allyn, 3Pound Health, Glottal Enterprises, Acrolite and Hiscock & Barclay.
MedTech is an active New York State association of pharmaceutical, bioscience and medical technology companies, their suppliers and service providers, and research universities. The organization boosts the growth and prosperity of its members by connecting them for collaboration, offering educational programs, sharing news and information, and advocating for the industry with government leaders. MedTech is celebrating its 10th year of connecting New York State’s Bio/Med industry. For more information, visit www.medtech.org and follow MedTech on social media at @MedTechAssoc.
The Advanced Medical Technology Association (AdvaMed) is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems.
Our members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.